ABOUT US
ABOUT US
Our Mission
To improve the lives of patients with serious diseases by pioneering therapies created with our revolutionary PROTAC protein degradation platform.
Transforming the Future for Patients
Arvinas is singularly focused on developing new options for patients in need, pioneering a new class of medicines based on targeted protein degradation.
For people living with cancers and other difficult-to-treat diseases, our approach has the proven potential to be transformative. Our proprietary PROTACs, or PROteolysis TArgeting Chimeras, are designed to work by harnessing the body’s own natural protein disposal system to degrade and remove disease-causing proteins.
This work led to the first U.S. Food and Drug Administration (FDA) approval of a PROTAC, a type of heterobifunctional protein degrader therapy.
We Are Undeterred by “Undruggable”
We’ve developed a broad technology platform focused on high-value targets to deliver more potent therapies and address the majority of proteins that evade inhibition—including those that have been deemed “undruggable” by traditional approaches.
At Arvinas, we work every day to unlock the full potential of PROTACs, developing a robust pipeline and partnering with the world’s leading drug development companies to bring new possibilities where they are needed most.
